Yes, losartan (ARB), SGLT2 inhibitors, and GLP-1 receptor agonists are not only safe but strongly recommended as foundational therapy for CKD patients without hyperkalemia.
All three medication classes—losartan (as an ARB), SGLT2 inhibitors, and GLP-1 receptor agonists—should be actively used in CKD patients as they provide proven kidney protection, cardiovascular benefits, and mortality reduction. 1
Losartan (ARB) Safety and Use in CKD
Losartan is recommended as first-line therapy for CKD patients with albuminuria, regardless of diabetes status. The KDIGO 2024 guidelines provide strong recommendations (1B) for starting ARBs in patients with severely increased albuminuria (A3) without diabetes, and for those with moderately-to-severely increased albuminuria (A2-A3) with diabetes 1.
Key Safety Parameters for ARBs:
- Continue ARB even when eGFR falls below 30 ml/min per 1.73 m² 1
- Monitor creatinine, potassium, and blood pressure within 2-4 weeks of initiation 1
- Continue therapy unless creatinine rises >30% within 4 weeks 1
- Since your patient is not hyperkalemic, this is ideal—hyperkalemia can often be managed with potassium-lowering measures rather than stopping the ARB 1
- Use the highest tolerated dose to achieve maximum benefit 1
Common pitfall to avoid: Do not discontinue ARBs prematurely when creatinine rises modestly (up to 30% is acceptable) or when eGFR declines, as this initial dip is hemodynamic and expected 1.
SGLT2 Inhibitor Safety and Use in CKD
SGLT2 inhibitors receive the strongest recommendation (1A) for adults with CKD and eGFR ≥20 ml/min per 1.73 m², particularly with albuminuria ≥200 mg/g or heart failure 1. This is independent of diabetes status—the 2024 KDIGO guidelines expanded recommendations beyond diabetic patients 1.
Key Safety Features:
- SGLT2 inhibitors actually reduce hyperkalemia risk, making them particularly safe in your non-hyperkalemic patient 2
- Once initiated, continue even if eGFR falls below 20 ml/min per 1.73 m² unless not tolerated 1
- The reversible eGFR decrease upon initiation is not an indication to stop therapy 1
- Temporarily withhold during prolonged fasting, surgery, or critical illness due to ketosis risk 1
SGLT2 inhibitors are considered foundational therapy in CKD, independent of BMI or diabetes status, and should be prioritized first 3.
GLP-1 Receptor Agonist Safety and Use in CKD
GLP-1 receptor agonists are recommended (1B) for patients with type 2 diabetes and CKD who haven't achieved glycemic targets despite metformin and SGLT2 inhibitors, or who cannot use those medications 1. Recent evidence shows kidney protection benefits extending beyond glucose control 4, 5.
Key Considerations:
- Prioritize long-acting GLP-1 RAs with documented cardiovascular benefits (like semaglutide) 1
- GLP-1 RAs are positioned as complementary adjunct therapy to SGLT2 inhibitors rather than foundational monotherapy 6, 3
- Meta-analyses consistently favor SGLT2 inhibitors over GLP-1 RAs for composite kidney outcomes, though both provide benefit 6
- Safe to combine with SGLT2 inhibitors and ARBs for additive cardiorenal protection 5, 2
Combination Therapy Strategy
The optimal approach is sequential combination therapy: Start with ARB (losartan) + SGLT2 inhibitor as foundational therapy, then add GLP-1 RA if needed for persistent albuminuria, cardiovascular risk, or metabolic control 4, 5, 3.
Monitoring Protocol:
- For ARB: Check potassium, creatinine, and BP at 2-4 weeks, then regularly 1
- For SGLT2i: Standard CKD monitoring frequency unchanged; expect initial eGFR dip 1
- For GLP-1 RA: Monitor glycemic control and cardiovascular parameters 1
Critical safety advantage: SGLT2 inhibitors mitigate hyperkalemia risk from ARBs, making the combination safer than ARB monotherapy 2. Your patient's absence of hyperkalemia is ideal for initiating this combination.
Blood Pressure Control
The 2025 AHA/ACC guidelines support intensive BP targets in CKD patients with diabetes, though the specific target depends on individual factors 7. ARBs, SGLT2 inhibitors, and GLP-1 RAs all contribute to BP reduction through complementary mechanisms 7, 4.
Bottom line: All three medications are not only safe but represent the current standard of care for CKD patients. The absence of hyperkalemia removes a key barrier, making this an optimal time to initiate or optimize all three classes for maximum kidney protection, cardiovascular benefit, and mortality reduction.